Picture of NovoCure logo

NVCR — NovoCure News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases

BRIEF-Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases

- NovoCure Limited NVCR.O:

  • NOVOCURE PROVIDES REGULATORY UPDATE ON U.S. FDA PREMARKET APPROVAL APPLICATION FOR OPTUNE MYA® FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER

  • NOVOCURE - FDA CITES UNCERTAINTY IN CLINICAL BENEFIT FOR OPTUNE MYA PMA NON-APPROVAL

  • NOVOCURE - FDA DOES NOT RAISE SAFETY CONCERNS FOR OPTUNE MYA

  • NOVOCURE - TO MEET FDA TO EXPLORE PMA APPROVAL OPTIONS WITHOUT ADDITIONAL STUDIES

  • NOVOCURE - RECEIVES FDA NOT APPROVABLE LETTER FOR OPTUNE MYA PMA APPLICATION

Source text: ID:nBw8GL7t8a

Further company coverage: NVCR.O


((Reuters.Briefs@thomsonreuters.com;))

Recent news on NovoCure

See all news